Related Experiment Video
Updated: Mar 29, 2026
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Unlocking KRAS: Navigating Its Molecular Biology and Treatment Landscape Among Gastrointestinal Malignancies
Austin Frisch1, Eric Martin1, Timothy Cannon2
1Inova Fairfax Department of Internal Medicine, Inova Fairfax Hospital, Fairfax, VA 22042, USA.
Abstract:
KRAS-targeted therapy has opened new doors in the world of oncology, and many trials are underway for KRAS specific treatments for gastrointestinal (GI) malignancies. Outlining the current state of KRAS therapy and the remaining research gaps pertaining to these deadly cancers is crucial for the development of future therapeutics. In this review, we focus on the relationship between KRAS and GI malignancies. Current therapies are discussed with an in-depth exploration of the KRAS gene and how it connects to pancreatic, colorectal and other GI malignancies. Promising clinical trials and future therapies are highlighted while discussing the molecular biology behind them. Specifically, trials focusing on upcoming KRAS on and off inhibitors in development as well as variant focused inhibitors targeting the more common mutations G12D and G12V. We discuss exciting new pan/multi KRAS inhibitors that have been successful in pre-clinical trials. More unique therapeutic options include KRAS T cell therapies, vaccines, and combination strategies with immunotherapy. Furthermore, we address the difficulties with KRAS therapy, and the potential future directions needed to overcome them. An in-depth current literature review was done along with a review of the active clinical trials for KRAS-targeted therapeutics involving GI malignancies.
Insights
KRAS-targeted therapy shows promise for gastrointestinal (GI) cancers. This review outlines current treatments, ongoing trials for KRAS inhibitors, and future directions for these deadly malignancies.
Area of Science:
- Oncology
- Molecular Biology
- Gastroenterology
Background:
- KRAS mutations are key drivers in various gastrointestinal (GI) malignancies.
- Targeted therapies for KRAS are emerging as a significant advancement in cancer treatment.
- Understanding the KRAS gene's role is vital for developing effective treatments for GI cancers.
Purpose of the Study:
- To review the current landscape of KRAS-targeted therapy for GI malignancies.
- To explore the molecular biology linking KRAS to pancreatic, colorectal, and other GI cancers.
- To highlight promising clinical trials and future therapeutic strategies for KRAS-driven cancers.
Main Methods:
- Comprehensive literature review of KRAS-targeted therapies.
- Analysis of current clinical trials for KRAS inhibitors.
- Exploration of molecular mechanisms and therapeutic targets.
Main Results:
- KRAS-targeted therapies, including specific inhibitors for mutations like G12D and G12V, are under active investigation.
- Newer approaches such as pan-KRAS inhibitors, T cell therapies, vaccines, and combination strategies show preclinical promise.
- Several clinical trials are evaluating novel KRAS inhibitors and combination therapies for GI malignancies.
Conclusions:
- KRAS-targeted therapy represents a rapidly evolving field with significant potential for treating GI cancers.
- Addressing challenges in KRAS therapy and exploring novel strategies are crucial for future progress.
- Continued research and clinical trials are essential to overcome resistance and improve outcomes for patients with KRAS-mutated GI malignancies.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers
02:07Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...